Cell and gene therapy | Life Sciences | Fieldfisher
Skip to main content
Select location France
  • Sectors
  • Cell and gene therapy

Cell and gene therapy

Cell and gene therapy (CGT) also known as advanced therapy medicinal products (ATMPs) is predicted to be the future of medicine.

CGT has the power to change the way we treat various chronic and life shortening illnesses that had previously been seen as incurable. With the paradigm potentially shifting from one of illness management to cure, CGT has the attention of the media, investors, regulators, pharmaceutical companies and the wider life sciences industry.

Why choose our CGT lawyers?


Even though CGT is attracting significant attention from various stakeholders, the route to market is far from straightforward with businesses having to overcome significant legal bottlenecks along the way to get treatments to patients.


Fieldfisher's pan-European life sciences lawyers have an in-depth understanding of the CGT space. We have a wealth of experience working with and advising the key players involved in the process from lab to patient on an international scale, from ambitious ATMP producers, usually academic institutions to development and manufacturing partners, larger pharmaceutical and biotechnology companies, investors, regulators and industry lobby groups.


With experts across regulatory, intellectual property, data protection, commercial and corporate law, we take a holistic approach to working with clients at every stage of their CGT journey.

White paper – The future of medicine: Cell and gene therapy

In this paper we look at the cell and gene therapy landscape across key hotspots in Europe, examining the opportunities and challenges for those involved, particularly the regulatory and commercial law issues blocking the pathway from lab to patient. This paper also discusses how national healthcare providers across Europe are opening their eyes and pockets to the substantial cost-savings that CGT can provide and with this change in approach, we look at what this means for the bright future of CGT in the UK and across the rest of Europe.

Request a copy

Cell and gene therapy latest news and views

View all linsights

Key contacts

View all lawyers